Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Am J Surg ; 218(2): 349-354, 2019 08.
Artículo en Inglés | MEDLINE | ID: mdl-30389119

RESUMEN

BACKGROUND: We sought to evaluate the post-operative outcomes of patients undergoing pancreaticoduodenectomy at a high volume academic community cancer center. METHODS: A retrospective review was performed of patients undergoing pancreaticoduodenectomy over a 10-year period. RESULTS: Over 10 years, 213 patients underwent pancreaticoduodenectomy. Median age was 66y. Most patients had significant comorbidities (median ASA = 3) and were overweight (median BMI = 27). Median operative time and blood loss were 253 min and 500 ml, respectively. 160 (75%) out of 213 patients had a malignant lesion on final pathology. 121 (76%) out of 160 had R0 resection. Median lymph nodes harvested was 13. Overall incidence of DGE was 31% (67/213), with clinically significant DGE in 15% (32/213). Pancreatic leak rate was 18% (37/213), with clinically significant leaks in 10% (21/213). Median length of stay was 8 days. Grade 3/4 morbidity rate was 21% (44/206), and 30-day mortality was 2% (5/213). CONCLUSIONS: At a high volume academic community cancer center, pancreaticoduodenectomy can be performed with excellent outcomes on par with any academic center or university hospital.


Asunto(s)
Neoplasias Duodenales/cirugía , Neoplasias Primarias Múltiples/cirugía , Neoplasias Pancreáticas/cirugía , Pancreaticoduodenectomía/estadística & datos numéricos , Centros Médicos Académicos , Adulto , Anciano , Anciano de 80 o más Años , Instituciones Oncológicas , Centros Comunitarios de Salud , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Resultado del Tratamiento , Estados Unidos , Adulto Joven
2.
Surg Oncol Clin N Am ; 25(2): 363-74, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-27013370

RESUMEN

Pancreatic neuroendocrine tumors are a rare group of neoplasms that arise from multipotent stem cells in the pancreatic ductal epithelium. Although they comprise only 1% to 2% of pancreatic neoplasms, their incidence is increasing. Most pancreatic neuroendocrine tumors are nonfunctioning, but they can secrete various hormones resulting in unique clinical syndromes. Clinicians must be aware of the diverse manifestations of this disease, as the key step to management of these rare tumors is to first suspect the diagnosis.


Asunto(s)
Tumores Neuroendocrinos/diagnóstico , Neoplasias Pancreáticas/diagnóstico , Humanos , Incidencia , Estadificación de Neoplasias , Tumores Neuroendocrinos/clasificación , Tumores Neuroendocrinos/epidemiología , Neoplasias Pancreáticas/clasificación , Neoplasias Pancreáticas/epidemiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...